NCT06938282View on ClinicalTrials.gov

An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2029

Conditions

Pancreatic Cancer

Interventions

DRUG

HRS-4642

HRS-4642 in Combination with Immunotherapy and Chemotherapy

All Listed Sponsors

lead

Shanghai Zhongshan Hospital

OTHER